Teva loses Copaxone patent appeal
The decision maintains exclusivity for Copaxone until May 24, 2014.
Mylan CEO Heather Bresch said, "We expect that it will allow Mylan to launch its generic version of Copaxone on May 25, 2014."
Teva sued Momenta/Sandoz and Mylan/Natco for infringement of patents covering the chemical composition of Copaxone, methods of using the product and processes for manufacturing the product, the latest of which expires on September 1, 2015. The appellate court declared other patents expiring in May 2014 and one patent expiring in September 2015 to be invalid. The appellate court specifically ruled that asserted claims of these patents are invalid for being indefinite.
Teva said, "Teva is disappointed with the courtís decision with respect to four of the 2014 patents and the 2015 patent and will appeal todayís decision. Importantly, any purported generic version of Copaxone needs to obtain the Food and Drug Administrationís (FDA) approval prior to being made available to the public. At this point, it is unclear what the requirements would be for approval of complex synthetic peptides."
Teva added, "Given the complexity of Copaxone, Teva believes unpredictable differences between a proposed generic product and Copaxone could lead to immunogenic effects in patients. The inability to fully characterize the active ingredients of the product leads many experts to believe that the only way to ensure the safety, efficacy and immunogenicity of any purported generic version of Copaxone would be through full-scale, placebo-controlled clinical trials with measured clinical endpoints (such as relapse rate) in multiple sclerosis patients."
In 2012, Copaxone accounted for $4 billion of Teva's $20 billion revenue.
Published by Globes [online], Israel business news - www.globes-online.com - on July 28, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options